HEPATOCELLULAR CARCINOMA
Clinical trials for HEPATOCELLULAR CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new HEPATOCELLULAR CARCINOMA trials appear
Sign up with your email to follow new studies for HEPATOCELLULAR CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for tough cancers: early trial tests novel drug combo
Disease control Not yet recruitingThis early-stage trial is testing a new drug called TB511, both by itself and in combination with the immunotherapy drug pembrolizumab (Keytruda). It aims to find a safe dose and see if it can shrink tumors in people with advanced solid cancers, including lung, prostate, colorect…
Matched conditions: HEPATOCELLULAR CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Twinpig Biolab, Inc. • Aim: Disease control
Last updated Apr 01, 2026 18:25 UTC
-
Scientists supercharge Patient's own cells to battle tough cancers
Disease control Not yet recruitingThis early-stage study is testing a new type of cell therapy for adults with advanced solid tumors that have not responded to standard treatments. Doctors will collect a patient's own immune cells, genetically modify them in a lab to better recognize and attack their cancer, and …
Matched conditions: HEPATOCELLULAR CARCINOMA
Phase: PHASE1 • Sponsor: Seattle Children's Hospital • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New hope for advanced liver cancer patients: aggressive treatment may open door to Life-Saving transplant
Disease control Not yet recruitingThis study looks back at whether combining multiple cancer treatments can shrink liver tumors enough to allow more patients to receive a liver transplant. Researchers will review medical records of 300 patients with advanced liver cancer who were initially considered ineligible f…
Matched conditions: HEPATOCELLULAR CARCINOMA
Sponsor: Ningbo Medical Center Lihuili Hospital • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
Starving cancer cells: new drug aims to boost effectiveness of common liver cancer procedure
Disease control Not yet recruitingThis study is testing if adding a drug called hydroxychloroquine to a standard liver cancer treatment (TACE) makes it work better. TACE works by cutting off a tumor's blood supply to starve it. Researchers think cancer cells survive this starvation by 'eating' themselves, a proce…
Matched conditions: HEPATOCELLULAR CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: VA Office of Research and Development • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New drug combo tested in fight against advanced liver cancer
Disease control Not yet recruitingThis study is testing a new drug called MRG006A, given together with existing immunotherapy and targeted therapy drugs, for people with advanced liver cancer that cannot be removed by surgery. The main goals are to find a safe and effective dose and to see if this combination can…
Matched conditions: HEPATOCELLULAR CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Lepu Biopharma Co., Ltd. • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
New Two-Pronged attack on inoperable liver cancer
Disease control Not yet recruitingThis study is testing a two-part treatment for liver cancer that cannot be surgically removed. Doctors will use tiny, drug-filled beads to block the tumor's blood supply and deliver chemotherapy directly, while patients also take an oral medication called Donafenib. The goal is t…
Matched conditions: HEPATOCELLULAR CARCINOMA
Sponsor: Xuhua Duan • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
New combo attack on liver cancer after radiation
Disease control Not yet recruitingThis small, early-stage study is testing whether adding a second immunotherapy drug helps control liver cancer after a targeted radiation treatment. About 20 patients with a specific type of liver cancer will receive radiation, then be assigned to get one of two different immunot…
Matched conditions: HEPATOCELLULAR CARCINOMA
Phase: PHASE1 • Sponsor: Virginia Commonwealth University • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
New combo attack aims to shrink liver tumors for surgery
Disease control Not yet recruitingThis study is testing if adding a targeted radiation treatment (radiotherapy) to a two-drug therapy helps shrink liver tumors in patients whose cancer cannot be removed by surgery initially. The goal is to see if this combination can shrink the tumors enough to make surgery possi…
Matched conditions: HEPATOCELLULAR CARCINOMA
Phase: PHASE2 • Sponsor: Hebei Medical University Fourth Hospital • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
New 'Seek-and-Destroy' radiation therapy tested for tough liver cancer
Disease control Not yet recruitingThis study is testing a new, targeted radiation treatment for people with advanced liver cancer that has spread. The treatment uses a drug that seeks out cancer cells by attaching to a specific protein (PSMA) found on their blood vessels. Researchers want to see if this approach …
Matched conditions: HEPATOCELLULAR CARCINOMA
Phase: PHASE2 • Sponsor: Melissa Lumish • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
New drug combo tested for Tough-to-Treat liver cancer
Disease control Not yet recruitingThis study is testing if adding an experimental drug called GKL-006 to a standard liver cancer treatment (TACE) is more effective and safe. It will involve about 48 adults with advanced liver cancer that cannot be removed by surgery. The main goal is to see if the combination shr…
Matched conditions: HEPATOCELLULAR CARCINOMA
Phase: PHASE2 • Sponsor: Beijing Gene Key Life Technology Co., Ltd • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
Could your COVID shot boost cancer treatment?
Disease control Not yet recruitingThis study looks back at medical records to see if getting a COVID mRNA vaccine shortly before starting immunotherapy helps people with advanced liver cancer. Researchers will analyze data from about 200 patients in Austria to check if vaccinated patients had better treatment res…
Matched conditions: HEPATOCELLULAR CARCINOMA
Sponsor: Medical University of Graz • Aim: Disease control
Last updated Mar 27, 2026 12:41 UTC
-
New drug combo aims to recharge immune system against tough liver cancer
Disease control Not yet recruitingThis study is testing whether adding a drug called gecacitinib to two other cancer drugs (donafenib and a PD-1 inhibitor) can help control advanced liver cancer that has started growing again after initial immunotherapy. It will enroll 35 adults to see if this combination is safe…
Matched conditions: HEPATOCELLULAR CARCINOMA
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
Can a Triple-Threat treatment make inoperable liver cancer operable?
Disease control Not yet recruitingThis study looks back at medical records to see if a combination of three types of treatment can help people with liver cancer that cannot be removed by surgery. The goal is to see if this approach can shrink tumors enough so that surgery becomes an option later. It will compare …
Matched conditions: HEPATOCELLULAR CARCINOMA
Sponsor: Ningbo Medical Center Lihuili Hospital • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
New Three-Pronged attack on inoperable liver cancer
Disease control Not yet recruitingThis study is testing a combination treatment for people with advanced liver cancer that cannot be removed by surgery. It combines a procedure that delivers chemotherapy directly to the liver tumor with two drugs that help the immune system fight cancer and block tumor blood supp…
Matched conditions: HEPATOCELLULAR CARCINOMA
Phase: NA • Sponsor: Third Affiliated Hospital, Sun Yat-Sen University • Aim: Disease control
Last updated Mar 24, 2026 12:03 UTC
-
New pill targets multiple cancers in patients out of options
Disease control Not yet recruitingThis is a first-in-human study testing a new oral drug called ACC-1898 in adults with advanced solid tumors who have run out of standard treatment options. The main goals are to find a safe dose and understand how the body processes the drug. Researchers will also look for early …
Matched conditions: HEPATOCELLULAR CARCINOMA
Phase: PHASE1 • Sponsor: AccSalus Biosciences, Inc. • Aim: Disease control
Last updated Mar 23, 2026 15:18 UTC
-
New Triple-Drug cocktail tested in battle against inoperable liver cancer
Disease control Not yet recruitingThis study is for adults with advanced liver cancer that cannot be removed by surgery. It compares two different drug combinations, both given alongside a standard procedure called TACE. The goal is to see which combination helps patients live longer and control their cancer bett…
Matched conditions: HEPATOCELLULAR CARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: Shanghai Zhongshan Hospital • Aim: Disease control
Last updated Mar 18, 2026 14:41 UTC
-
Hot & cold cancer zap trial seeks to boost Body's defenses
Disease control Not yet recruitingThis study is testing a treatment that uses both freezing and heating to destroy liver tumors. It aims to see if this method is safe, controls the cancer, and triggers the body's own immune system to fight the disease. The trial will involve 120 patients with primary liver cancer…
Matched conditions: HEPATOCELLULAR CARCINOMA
Phase: NA • Sponsor: Fudan University • Aim: Disease control
Last updated Mar 16, 2026 15:26 UTC
-
Targeted radiation zaps inoperable liver tumors in new trial
Disease control Not yet recruitingThis study is testing a targeted radiation treatment for people with early-stage liver cancer that cannot be removed by surgery. Doctors will inject tiny radioactive beads directly into the blood vessels feeding the tumor to deliver a high dose of radiation. The main goals are to…
Matched conditions: HEPATOCELLULAR CARCINOMA
Phase: NA • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Mar 16, 2026 15:25 UTC
-
New drug combo aims to extend life for advanced liver cancer patients
Disease control Not yet recruitingThis study is for people with advanced liver cancer who are already receiving durvalumab after initial treatment with tremelimumab and durvalumab. Researchers want to see if adding an experimental oral drug called zanzalintinib to the ongoing durvalumab treatment helps people liv…
Matched conditions: HEPATOCELLULAR CARCINOMA
Phase: PHASE2 • Sponsor: Amit Mahipal • Aim: Disease control
Last updated Mar 09, 2026 14:26 UTC
-
Doctors test safer scan to spot liver Cancer's return
Diagnosis Not yet recruitingThis study is testing a new type of ultrasound scan to see if it can accurately tell whether a liver cancer treatment has worked. It will involve 200 adults who have had a heat-based treatment to destroy small liver tumors. The goal is to see if this safer, radiation-free scan ca…
Matched conditions: HEPATOCELLULAR CARCINOMA
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Diagnosis
Last updated Mar 19, 2026 14:56 UTC
-
New hope to fight devastating weight loss in liver cancer
Symptom relief Not yet recruitingThis study is testing whether adding a drug called nanocrystalline megestrol acetate to standard liver cancer treatment can help patients who are experiencing severe, disease-related weight loss and poor appetite. The goal is to see if this combination helps people eat better and…
Matched conditions: HEPATOCELLULAR CARCINOMA
Phase: PHASE3 • Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd. • Aim: Symptom relief
Last updated Mar 30, 2026 14:32 UTC
-
New MRI scan seeks clues in liver cancer
Knowledge-focused Not yet recruitingThis study aims to understand liver cancer better by comparing advanced MRI scans in two groups: people with untreated liver cancer and healthy volunteers. It uses a special MRI machine to take detailed pictures of the liver. The goal is to see if these new scan types can reveal …
Matched conditions: HEPATOCELLULAR CARCINOMA
Phase: NA • Sponsor: Philips Clinical & Medical Affairs Global • Aim: Knowledge-focused
Last updated Mar 23, 2026 15:16 UTC